There is no better time to buy CRO than it is now.
Not my strategy usually, but:
* the market is saturated with competitors, yet they are failing, CDC is thriving
* CDC have a vision and plan for CRO and their ecosystem that they stick to
* CRO massively undervalued
* Perks (and options to use CRO) still there and even with the special measures ending, CDC will introduce ways to use CRO beyond giftcards and 10% rebates
* the supercharger is a genius way to “hit” launchpad’s market share and incentivise CDC users to interact with the Exchange (and that comes from an Exchange sceptic)
In summary, buy the dip. You’ll be glad you did.